BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Mells G, Kendrick S, Dyson JK, Jones DEJ; UK-AIH Consortium. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology 2018;68:1487-97. [PMID: 29663477 DOI: 10.1002/hep.30031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther 2020;52:1134-49. [PMID: 32794592 DOI: 10.1111/apt.16035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Janik MK, Wunsch E, Raszeja-Wyszomirska J, Krawczyk M, Milkiewicz P. Depression: An Overlooked Villain in Autoimmune Hepatitis? Hepatology 2019;70:2232-3. [PMID: 30773711 DOI: 10.1002/hep.30568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. The Lancet Gastroenterology & Hepatology 2018;3:363-70. [DOI: 10.1016/s2468-1253(18)30043-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Cortesi PA, Conti S, Scalone L, Jaffe A, Ciaccio A, Okolicsanyi S, Rota M, Fabris L, Colledan M, Fagiuoli S, Belli LS, Cesana G, Strazzabosco M, Mantovani LG. Health related quality of life in chronic liver diseases. Liver Int 2020;40:2630-42. [PMID: 32851764 DOI: 10.1111/liv.14647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tang S, Gong Y, Liu M, Yang D, Tang K. Do Drug Accessibility and OOP Burden Affect Health-Related Quality of Life of Patients With Chronic Diseases? - EQ-5D-5L Evaluation Evidence From Five Districts in China. Front Public Health 2021;9:656104. [PMID: 33791272 DOI: 10.3389/fpubh.2021.656104] [Reference Citation Analysis]
6 Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver 2020;14:430-8. [PMID: 32301319 DOI: 10.5009/gnl19261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
7 van den Brand FF, Snijders RJALM, de Boer YS, Verwer BJ, van Nieuwkerk CMJ, Bloemena E, Kuiken SD, Drenth JPH, Bouma G. Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: A prospective observational study. Eur J Intern Med 2021;90:30-6. [PMID: 33865679 DOI: 10.1016/j.ejim.2021.03.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lloyd C, Leighton J, Wong LL, Goulding A, Brownlee A, Gray P, Culver E, Halliday N, Thorburn D, Heneghan MA, Jones DEJ, Exley C, Dyson JK. Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma. Dig Dis Sci 2022. [PMID: 35579795 DOI: 10.1007/s10620-022-07525-5] [Reference Citation Analysis]
9 Grønkjær LL, Lauridsen MM. Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review. JHEP Rep 2021;3:100370. [PMID: 34805816 DOI: 10.1016/j.jhepr.2021.100370] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
10 Jones E, Watkins M, Anderson E, Gelow K, Green K, Draucker C, Lammert C. Overlooked Symptoms in Autoimmune Hepatitis Negatively Impact Many Facets of Life. Dig Dis Sci 2022. [PMID: 35441275 DOI: 10.1007/s10620-022-07484-x] [Reference Citation Analysis]
11 Gordon VM, Adhikary R, Aithal GP, Appleby V, Das D, Day J, Delahooke T, Dixon S, Elphick D, Hardie C, Heneghan M, Hoeroldt B, Hooper P, Hutchinson J, Jones RL, Khan F, Metcalf J, Nkhoma A, Pelitari S, Prince M, Prosser A, Saksena S, Sathyanarayana V, Vani D, Yeoman A, Gleeson D. Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH). Frontline Gastroenterol 2022;13:126-32. [DOI: 10.1136/flgastro-2020-101661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Snijders RJ, Milkiewicz P, Schramm C, Gevers TJ. Health-related quality of life in autoimmune hepatitis. World J Hepatol 2021; 13(11): 1642-1652 [PMID: 34904034 DOI: 10.4254/wjh.v13.i11.1642] [Reference Citation Analysis]
13 Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology 2020;73:1496-506. [DOI: 10.1016/j.jhep.2020.07.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
14 Dyson JK, De Martin E, Dalekos GN, Drenth JP, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW; the IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther 2019;49:528-36. [DOI: 10.1111/apt.15111] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
15 Cuarterolo ML, Ciocca M, López S, Araujo M, Álvarez F. Autoimmune Hepatitis in Children: Prednisone Plus Azathioprine Versus Cyclosporine: A Randomized Trial. Journal of Pediatric Gastroenterology & Nutrition 2020;71:376-80. [DOI: 10.1097/mpg.0000000000002776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vogelbacher L, Thimme R, Böttler T. [Autoimmune Hepatitis - What is important for clinical practice?]. Dtsch Med Wochenschr 2022;147:470-80. [PMID: 35405751 DOI: 10.1055/a-1520-4214] [Reference Citation Analysis]
18 Wilder JM, Evon DM, Proeschold-Bell RJ, Yao J, Sohail MM, Niedzwiecki D, Makarushka C, Hodge T, Muir AJ. Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. J Viral Hepat 2021;28:699-709. [PMID: 33476429 DOI: 10.1111/jvh.13474] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mathur K, Vuppalanchi V, Gelow K, Vuppalanchi R, Lammert C. Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis. Dig Dis Sci 2020;65:322-8. [PMID: 31363952 DOI: 10.1007/s10620-019-05756-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Tu H, Chen D, Cai C, Du Q, Lin H, Pan T, Sheng L, Xu Y, Teng T, Tu J, Lin Z, Wang X, Wang R, Xu L, Chen Y. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation. J Cell Mol Med 2020;24:1256-67. [PMID: 31808606 DOI: 10.1111/jcmm.14750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
21 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 200] [Cited by in F6Publishing: 157] [Article Influence: 100.0] [Reference Citation Analysis]
22 Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int 2019;39:1002-13. [DOI: 10.1111/liv.14062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
23 Wang H, Feng X, Yan W, Tian D. Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients. Front Immunol 2020;11:575572. [PMID: 33117375 DOI: 10.3389/fimmu.2020.575572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 2018;48:951-60. [PMID: 30226274 DOI: 10.1111/apt.14968] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
25 Chapman RW. Provision and standards of care for treatment and follow-up of patients with auto-immune hepatitis (AIH). Frontline Gastroenterol 2022;13:96-7. [DOI: 10.1136/flgastro-2021-101928] [Reference Citation Analysis]
26 Schramm C. Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life. Clin Liver Dis (Hoboken) 2019;14:33-6. [PMID: 31391935 DOI: 10.1002/cld.816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Takahashi A, Abe M, Yasunaka T, Arinaga-Hino T, Abe K, Takaki A, Torimura T, Zeniya M, Yoshizawea K, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H, Ohira H. Quality of life among patients with autoimmune hepatitis in remission: A comparative study. Medicine (Baltimore) 2020;99:e22764. [PMID: 33120784 DOI: 10.1097/MD.0000000000022764] [Reference Citation Analysis]
28 Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Front Public Health 2021;9:675523. [PMID: 34268287 DOI: 10.3389/fpubh.2021.675523] [Reference Citation Analysis]
29 Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, Wang FS, Wei L, Wang Q, Sun Y, Hong Y, Rao H, Efe C, Lau G, Payawal D, Gani R, Lindor K, Jafri W, Omata M, Sarin SK. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int 2021;15:223-57. [PMID: 33942203 DOI: 10.1007/s12072-021-10170-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
30 Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2021;27:58-69. [PMID: 33291862 DOI: 10.3350/cmh.2020.0189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int 2019;39:610-20. [DOI: 10.1111/liv.14051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
32 Xia D, Chen D, Cai T, Zhu L, Lin Y, Yu S, Zhu K, Wang X, Xu L, Chen Y. Nimbolide attenuated the inflammation in the liver of autoimmune hepatitis's mice through regulation of HDAC3. Toxicol Appl Pharmacol 2021;434:115795. [PMID: 34780724 DOI: 10.1016/j.taap.2021.115795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chapman RW, Aspinall RJ, Trivedi P, Wright G, Heneghan M. Challenges in the use of corticosteroids in the management of autoimmune hepatitis. Br J Hosp Med (Lond) 2019;80:594-9. [PMID: 31589514 DOI: 10.12968/hmed.2019.80.10.594] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]